| Literature DB >> 20922194 |
Margien L Seinen1, Dirk P van Asseldonk, Chris J J Mulder, Nanne K H de Boer.
Abstract
Conventional thiopurines are considered to be effective and safe in the treatment of inflammatory bowel disease (IBD) patients; unfortunately more than 50% of patients discontinue thiopurine therapy, mainly due to the development of intractable adverse events. In recent years, the use of 6-thioguanine has been proposed as an alternative thiopurine in IBD patients failing to tolerate or to respond to conventional thiopurine therapy. In this clinical review, we describe the rationale for 6-thioguanine therapy and discuss the reported hepatotoxicity of 6-thioguanine (especially nodular regenerative hyperplasia). We propose expert-based guidelines for balanced treatment.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20922194
Source DB: PubMed Journal: J Gastrointestin Liver Dis ISSN: 1841-8724 Impact factor: 2.008